Skip to main content
. 2017 Feb 4;8(9):14294–14305. doi: 10.18632/oncotarget.15104

Figure 8. The levels of pAMPK and pAP-2α are increased in human individuals taking pravastatin and in AAA patients.

Figure 8

A. and B. The profiles of these patients were shown in Supplementary Table S9. The peripheral blood cells were collected from human subjects with or without taking pravastatin (20 mg per day) for 0.5-3 years. The levels of pAMPK-T172 and pAP-2α-S219 in total cell lysates were detected by Western blot A. and serum levels of MMP2 were determined by ELISA B.. C.-E. The demographic data were presented in Supplementary Table S10. The levels of pAMPK and pAP-2α were assayed by IHC C.. The quantitative analyses of pAMPK D. and pAP-2α E. from C were shown. 8 human subjects in each group in A and B. 6 human subjects in each group in C.-E. Unpaired student's t-test was used for all statistical comparisons. *P < 0.05 vs. Control patients B. or Non-AAA patients D., E.